A treat-to-target study of upadacitinib in atopic dermatitis showed that dosing can be adjusted depending on early patient response without serious adverse effects.
Former SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, with established track record for leading a portfolio ...
With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...
It has already been speculated that AstraZeneca's termination of a plan to invest £450 million in a new vaccine manufacturing ...
The government has identified life sciences as one of the sectors with the highest potential for growth in the UK and plans to make it a key pillar of its upcoming industry strategy. The ...
LUND, SE / ACCESS Newswire / March 20, 2025 /Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) ...
A novel approach using native mass spectrometry has significantly advanced the understanding of stabilization mechanisms of ...
UnitedHealth Group's pharmacy benefit manager, Optum Rx, said on Wednesday it would ease requirements to get insurance ...
1hon MSN
The United States pharmaceutical lobby has complained to US President Donald Trump that Australia’s Pharmaceutical Benefits ...
Despite Monday’s market uptick, broader indices remain lower year-to-date as investors grapple with uncertainties surrounding ...
The United States pharmaceutical lobby has complained to US President Donald Trump that Australia's Pharmaceutical Benefits ...
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the acquisition of Xbrane Biopharma AB ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback